| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Depressive Disorder, Major | 105 | 2024 | 4805 | 8.080 |
Why?
|
| Bipolar Disorder | 114 | 2024 | 5128 | 7.330 |
Why?
|
| Antidepressive Agents | 63 | 2024 | 2901 | 5.570 |
Why?
|
| Electronic Health Records | 44 | 2024 | 4863 | 4.010 |
Why?
|
| Natural Language Processing | 20 | 2022 | 1198 | 2.350 |
Why?
|
| Irritable Mood | 6 | 2025 | 196 | 2.260 |
Why?
|
| Fluoxetine | 13 | 2015 | 731 | 2.080 |
Why?
|
| Suicide | 13 | 2023 | 1606 | 2.010 |
Why?
|
| Depression | 32 | 2024 | 8223 | 1.840 |
Why?
|
| Pharmacogenetics | 19 | 2020 | 682 | 1.830 |
Why?
|
| Citalopram | 15 | 2022 | 402 | 1.800 |
Why?
|
| Mental Disorders | 23 | 2024 | 6870 | 1.770 |
Why?
|
| Induced Pluripotent Stem Cells | 15 | 2023 | 1884 | 1.760 |
Why?
|
| Schizophrenia | 28 | 2024 | 6971 | 1.740 |
Why?
|
| Suicide, Attempted | 18 | 2022 | 1412 | 1.730 |
Why?
|
| Antidepressive Agents, Second-Generation | 8 | 2014 | 490 | 1.650 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 20 | 2020 | 1987 | 1.590 |
Why?
|
| Depressive Disorder | 21 | 2018 | 3712 | 1.540 |
Why?
|
| Antimanic Agents | 13 | 2020 | 523 | 1.480 |
Why?
|
| Delirium | 7 | 2021 | 1699 | 1.440 |
Why?
|
| Patient Readmission | 7 | 2021 | 3282 | 1.410 |
Why?
|
| Genome-Wide Association Study | 42 | 2024 | 12803 | 1.390 |
Why?
|
| Psychiatry | 10 | 2020 | 1715 | 1.370 |
Why?
|
| Anxiety Disorders | 15 | 2024 | 2739 | 1.350 |
Why?
|
| Authorship | 4 | 2022 | 289 | 1.350 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 14 | 2021 | 3719 | 1.350 |
Why?
|
| Humans | 375 | 2025 | 765926 | 1.340 |
Why?
|
| Calcium Channels, L-Type | 8 | 2017 | 243 | 1.330 |
Why?
|
| Female | 247 | 2025 | 396141 | 1.320 |
Why?
|
| Cytochrome P-450 Enzyme System | 6 | 2017 | 423 | 1.300 |
Why?
|
| Adult | 182 | 2025 | 223088 | 1.280 |
Why?
|
| Mood Disorders | 6 | 2021 | 1127 | 1.270 |
Why?
|
| Male | 221 | 2025 | 363815 | 1.270 |
Why?
|
| Psychiatric Status Rating Scales | 37 | 2022 | 6013 | 1.270 |
Why?
|
| Medication Adherence | 8 | 2020 | 2190 | 1.260 |
Why?
|
| Thiophenes | 6 | 2012 | 570 | 1.240 |
Why?
|
| Polymorphism, Single Nucleotide | 51 | 2021 | 16039 | 1.180 |
Why?
|
| Lithium | 7 | 2024 | 599 | 1.160 |
Why?
|
| Bibliometrics | 3 | 2021 | 356 | 1.150 |
Why?
|
| Antipsychotic Agents | 17 | 2019 | 3075 | 1.140 |
Why?
|
| Microglia | 7 | 2024 | 1369 | 1.090 |
Why?
|
| Narration | 3 | 2021 | 223 | 1.060 |
Why?
|
| Personality Disorders | 4 | 2020 | 727 | 1.050 |
Why?
|
| Psychotropic Drugs | 9 | 2019 | 880 | 1.020 |
Why?
|
| Genetic Predisposition to Disease | 36 | 2021 | 18074 | 1.020 |
Why?
|
| Cohort Studies | 46 | 2024 | 41680 | 0.980 |
Why?
|
| Middle Aged | 122 | 2025 | 223016 | 0.970 |
Why?
|
| Central Nervous System Stimulants | 5 | 2024 | 1166 | 0.940 |
Why?
|
| Drug Discovery | 3 | 2019 | 1062 | 0.940 |
Why?
|
| Self Report | 8 | 2025 | 3768 | 0.940 |
Why?
|
| Hospitals, General | 3 | 2021 | 803 | 0.920 |
Why?
|
| Genetic Loci | 7 | 2019 | 2630 | 0.920 |
Why?
|
| Genotype | 37 | 2020 | 13026 | 0.900 |
Why?
|
| Lithium Carbonate | 4 | 2014 | 179 | 0.890 |
Why?
|
| Psychopathology | 5 | 2024 | 434 | 0.890 |
Why?
|
| Hospitalization | 17 | 2024 | 10810 | 0.880 |
Why?
|
| Databases, Genetic | 4 | 2020 | 1756 | 0.870 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 4 | 2019 | 501 | 0.850 |
Why?
|
| Benzodiazepines | 9 | 2012 | 1136 | 0.850 |
Why?
|
| Psychotic Disorders | 15 | 2024 | 3274 | 0.840 |
Why?
|
| Neural Stem Cells | 6 | 2023 | 897 | 0.840 |
Why?
|
| Pandemics | 16 | 2024 | 8721 | 0.840 |
Why?
|
| Suicidal Ideation | 5 | 2023 | 1465 | 0.830 |
Why?
|
| Biomarkers, Pharmacological | 4 | 2015 | 161 | 0.820 |
Why?
|
| Catechol O-Methyltransferase | 6 | 2016 | 250 | 0.820 |
Why?
|
| Publishing | 2 | 2021 | 836 | 0.810 |
Why?
|
| Trust | 2 | 2024 | 532 | 0.800 |
Why?
|
| Lithium Compounds | 8 | 2020 | 226 | 0.800 |
Why?
|
| Logistic Models | 26 | 2024 | 13273 | 0.800 |
Why?
|
| Biomedical Research | 5 | 2023 | 3458 | 0.790 |
Why?
|
| Anger | 5 | 2008 | 402 | 0.790 |
Why?
|
| Massachusetts | 15 | 2024 | 8882 | 0.750 |
Why?
|
| Medical Informatics | 2 | 2018 | 743 | 0.750 |
Why?
|
| Coronavirus Infections | 5 | 2022 | 3109 | 0.740 |
Why?
|
| DNA Copy Number Variations | 7 | 2022 | 2045 | 0.740 |
Why?
|
| Drug Prescriptions | 4 | 2022 | 1662 | 0.740 |
Why?
|
| Periodicals as Topic | 4 | 2022 | 1463 | 0.740 |
Why?
|
| Pneumonia, Viral | 5 | 2022 | 3231 | 0.740 |
Why?
|
| Treatment Outcome | 67 | 2024 | 65194 | 0.740 |
Why?
|
| Patient Discharge | 4 | 2018 | 3460 | 0.730 |
Why?
|
| Calcium Channel Blockers | 3 | 2015 | 685 | 0.730 |
Why?
|
| ROC Curve | 13 | 2024 | 3612 | 0.720 |
Why?
|
| Adolescent | 60 | 2025 | 88811 | 0.710 |
Why?
|
| Synapses | 4 | 2020 | 1758 | 0.710 |
Why?
|
| Academic Medical Centers | 4 | 2020 | 2782 | 0.710 |
Why?
|
| Decision Support Techniques | 6 | 2014 | 2004 | 0.700 |
Why?
|
| Postpartum Hemorrhage | 2 | 2021 | 275 | 0.690 |
Why?
|
| Conflict of Interest | 4 | 2018 | 556 | 0.690 |
Why?
|
| Affect | 10 | 2015 | 1494 | 0.690 |
Why?
|
| Social Isolation | 1 | 2023 | 366 | 0.680 |
Why?
|
| Multifactorial Inheritance | 9 | 2021 | 1426 | 0.670 |
Why?
|
| Length of Stay | 8 | 2024 | 6486 | 0.660 |
Why?
|
| Nitroprusside | 1 | 2019 | 271 | 0.640 |
Why?
|
| Phenotype | 30 | 2024 | 16714 | 0.630 |
Why?
|
| Emergency Services, Psychiatric | 1 | 2019 | 65 | 0.630 |
Why?
|
| Reward | 8 | 2019 | 980 | 0.620 |
Why?
|
| Randomized Controlled Trials as Topic | 15 | 2012 | 10380 | 0.610 |
Why?
|
| Aged | 60 | 2025 | 171163 | 0.600 |
Why?
|
| Arousal | 2 | 2018 | 1174 | 0.590 |
Why?
|
| Rett Syndrome | 1 | 2019 | 163 | 0.590 |
Why?
|
| Isradipine | 2 | 2015 | 12 | 0.580 |
Why?
|
| Neuronal Plasticity | 4 | 2022 | 1446 | 0.580 |
Why?
|
| Models, Statistical | 9 | 2021 | 5088 | 0.580 |
Why?
|
| Accidental Falls | 2 | 2017 | 1079 | 0.580 |
Why?
|
| New England | 6 | 2018 | 1059 | 0.580 |
Why?
|
| Risk Assessment | 16 | 2024 | 24275 | 0.580 |
Why?
|
| Psychotherapy | 4 | 2018 | 1648 | 0.570 |
Why?
|
| Coronavirus | 1 | 2020 | 155 | 0.570 |
Why?
|
| Young Adult | 40 | 2025 | 59857 | 0.570 |
Why?
|
| Drug Therapy, Combination | 18 | 2019 | 6306 | 0.570 |
Why?
|
| Receptors, Formyl Peptide | 1 | 2018 | 146 | 0.570 |
Why?
|
| Costs and Cost Analysis | 3 | 2018 | 1666 | 0.560 |
Why?
|
| Double-Blind Method | 19 | 2020 | 12417 | 0.560 |
Why?
|
| Publications | 1 | 2019 | 195 | 0.560 |
Why?
|
| Pregnancy Complications, Infectious | 6 | 2025 | 2184 | 0.560 |
Why?
|
| Prenatal Exposure Delayed Effects | 4 | 2024 | 2538 | 0.550 |
Why?
|
| Behavioral Symptoms | 1 | 2019 | 187 | 0.550 |
Why?
|
| Wounds, Gunshot | 1 | 2023 | 586 | 0.550 |
Why?
|
| Prevalence | 17 | 2024 | 15828 | 0.550 |
Why?
|
| Retrospective Studies | 43 | 2024 | 81537 | 0.550 |
Why?
|
| Intensive Care Units | 3 | 2021 | 3799 | 0.550 |
Why?
|
| Genetic Association Studies | 6 | 2017 | 2744 | 0.540 |
Why?
|
| Hospital Mortality | 2 | 2021 | 5339 | 0.540 |
Why?
|
| Prefrontal Cortex | 7 | 2023 | 2223 | 0.530 |
Why?
|
| Hospital Departments | 1 | 2017 | 134 | 0.530 |
Why?
|
| Drug Repositioning | 2 | 2018 | 244 | 0.530 |
Why?
|
| Documentation | 2 | 2020 | 911 | 0.530 |
Why?
|
| Drug Interactions | 3 | 2017 | 1416 | 0.530 |
Why?
|
| Desipramine | 2 | 2015 | 183 | 0.530 |
Why?
|
| Autistic Disorder | 2 | 2016 | 1238 | 0.530 |
Why?
|
| Computer Security | 1 | 2018 | 261 | 0.530 |
Why?
|
| Cation Transport Proteins | 1 | 2019 | 325 | 0.520 |
Why?
|
| Anti-Anxiety Agents | 2 | 2018 | 403 | 0.510 |
Why?
|
| Delivery of Health Care | 4 | 2018 | 5364 | 0.510 |
Why?
|
| Spasms, Infantile | 1 | 2019 | 300 | 0.510 |
Why?
|
| Comorbidity | 27 | 2024 | 10575 | 0.510 |
Why?
|
| Cytidine Diphosphate Choline | 1 | 2015 | 29 | 0.500 |
Why?
|
| Drug Evaluation, Preclinical | 4 | 2018 | 1331 | 0.500 |
Why?
|
| Huntington Disease | 2 | 2015 | 1147 | 0.500 |
Why?
|
| Nerve Tissue Proteins | 10 | 2017 | 4394 | 0.500 |
Why?
|
| Accidents | 1 | 2016 | 164 | 0.500 |
Why?
|
| Firearms | 1 | 2023 | 630 | 0.490 |
Why?
|
| Drug Industry | 2 | 2016 | 791 | 0.490 |
Why?
|
| Case-Control Studies | 29 | 2024 | 22228 | 0.490 |
Why?
|
| Biological Specimen Banks | 2 | 2019 | 787 | 0.490 |
Why?
|
| Nootropic Agents | 2 | 2015 | 159 | 0.480 |
Why?
|
| Severity of Illness Index | 24 | 2021 | 15878 | 0.480 |
Why?
|
| Pregnancy Complications | 6 | 2024 | 2970 | 0.480 |
Why?
|
| Pregnancy | 27 | 2025 | 30230 | 0.470 |
Why?
|
| Early Diagnosis | 1 | 2020 | 1186 | 0.470 |
Why?
|
| Financial Support | 2 | 2005 | 116 | 0.470 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 2 | 2012 | 88 | 0.470 |
Why?
|
| Antidepressive Agents, Tricyclic | 3 | 2014 | 427 | 0.470 |
Why?
|
| Workload | 1 | 2020 | 848 | 0.470 |
Why?
|
| Longitudinal Studies | 24 | 2024 | 14745 | 0.460 |
Why?
|
| Central Nervous System Agents | 1 | 2015 | 72 | 0.460 |
Why?
|
| Drug Therapy | 2 | 2008 | 504 | 0.460 |
Why?
|
| Long QT Syndrome | 2 | 2017 | 474 | 0.460 |
Why?
|
| Patient Admission | 3 | 2021 | 1365 | 0.460 |
Why?
|
| Cocaine-Related Disorders | 2 | 2015 | 458 | 0.460 |
Why?
|
| Sexual Dysfunctions, Psychological | 2 | 2009 | 193 | 0.450 |
Why?
|
| Death | 1 | 2019 | 686 | 0.450 |
Why?
|
| Hospitals | 4 | 2024 | 3886 | 0.450 |
Why?
|
| Confidentiality | 1 | 2018 | 607 | 0.450 |
Why?
|
| Risk Factors | 47 | 2023 | 74850 | 0.450 |
Why?
|
| Mexican Americans | 1 | 2015 | 165 | 0.450 |
Why?
|
| United States | 26 | 2025 | 72909 | 0.450 |
Why?
|
| Drug Resistance | 6 | 2012 | 1588 | 0.450 |
Why?
|
| Trinucleotide Repeats | 1 | 2015 | 257 | 0.450 |
Why?
|
| Central Nervous System | 2 | 2019 | 1343 | 0.440 |
Why?
|
| Neurons | 11 | 2023 | 9527 | 0.430 |
Why?
|
| Brain-Derived Neurotrophic Factor | 2 | 2015 | 606 | 0.430 |
Why?
|
| Clinical Trials as Topic | 9 | 2020 | 8037 | 0.420 |
Why?
|
| Vaccination | 2 | 2025 | 3430 | 0.420 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2015 | 497 | 0.420 |
Why?
|
| Risk-Taking | 1 | 2019 | 1021 | 0.420 |
Why?
|
| National Institute of Mental Health (U.S.) | 4 | 2024 | 107 | 0.420 |
Why?
|
| Interleukins | 1 | 2018 | 789 | 0.420 |
Why?
|
| Methadone | 1 | 2015 | 318 | 0.410 |
Why?
|
| Receptor, Serotonin, 5-HT1A | 1 | 2012 | 57 | 0.400 |
Why?
|
| Chromosome Duplication | 1 | 2012 | 79 | 0.400 |
Why?
|
| Benzothiazoles | 1 | 2013 | 245 | 0.400 |
Why?
|
| Patient Participation | 2 | 2019 | 1447 | 0.400 |
Why?
|
| Schizophrenic Psychology | 3 | 2017 | 1645 | 0.390 |
Why?
|
| Depression, Postpartum | 1 | 2017 | 354 | 0.390 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 1 | 2012 | 66 | 0.390 |
Why?
|
| Remission Induction | 5 | 2020 | 2413 | 0.390 |
Why?
|
| Cell Culture Techniques | 2 | 2016 | 1650 | 0.380 |
Why?
|
| Carrier Proteins | 4 | 2018 | 4909 | 0.380 |
Why?
|
| Anxiety | 6 | 2024 | 4669 | 0.380 |
Why?
|
| Insurance Claim Review | 1 | 2016 | 744 | 0.380 |
Why?
|
| Psychoses, Substance-Induced | 2 | 2024 | 98 | 0.370 |
Why?
|
| Genetic Variation | 9 | 2018 | 6612 | 0.370 |
Why?
|
| Valproic Acid | 2 | 2011 | 444 | 0.370 |
Why?
|
| Potassium Channels, Tandem Pore Domain | 2 | 2010 | 57 | 0.370 |
Why?
|
| Medicare Part D | 1 | 2016 | 355 | 0.370 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2012 | 386 | 0.370 |
Why?
|
| Mitochondria | 3 | 2020 | 3669 | 0.370 |
Why?
|
| Avoidance Learning | 3 | 2010 | 248 | 0.360 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2024 | 1852 | 0.360 |
Why?
|
| Patient Compliance | 3 | 2019 | 2693 | 0.360 |
Why?
|
| Communication | 2 | 2023 | 3908 | 0.360 |
Why?
|
| Receptors, AMPA | 2 | 2009 | 335 | 0.350 |
Why?
|
| Personality Inventory | 8 | 2012 | 1018 | 0.350 |
Why?
|
| Disease Progression | 4 | 2020 | 13614 | 0.350 |
Why?
|
| Weight Gain | 5 | 2023 | 2356 | 0.340 |
Why?
|
| Brain | 23 | 2024 | 27179 | 0.340 |
Why?
|
| Drug Costs | 3 | 2016 | 1194 | 0.340 |
Why?
|
| Pregnancy Outcome | 4 | 2024 | 2969 | 0.340 |
Why?
|
| Journal Impact Factor | 2 | 2022 | 157 | 0.330 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 2726 | 0.330 |
Why?
|
| Cognition | 9 | 2023 | 7043 | 0.330 |
Why?
|
| Practice Guidelines as Topic | 8 | 2018 | 7423 | 0.330 |
Why?
|
| Renal Insufficiency | 1 | 2015 | 810 | 0.330 |
Why?
|
| Intention | 1 | 2012 | 346 | 0.330 |
Why?
|
| Forecasting | 1 | 2018 | 2936 | 0.330 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2014 | 723 | 0.320 |
Why?
|
| Models, Biological | 3 | 2021 | 9443 | 0.320 |
Why?
|
| Gene Expression Profiling | 3 | 2020 | 9525 | 0.320 |
Why?
|
| Thinking | 1 | 2012 | 320 | 0.320 |
Why?
|
| Organoids | 4 | 2023 | 740 | 0.320 |
Why?
|
| Social Environment | 1 | 2014 | 1010 | 0.320 |
Why?
|
| Aged, 80 and over | 13 | 2022 | 59496 | 0.310 |
Why?
|
| Neuroglia | 1 | 2014 | 963 | 0.310 |
Why?
|
| Computational Biology | 1 | 2020 | 3562 | 0.310 |
Why?
|
| Pattern Recognition, Visual | 3 | 2010 | 820 | 0.310 |
Why?
|
| Alleles | 10 | 2016 | 6891 | 0.300 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2018 | 1894 | 0.300 |
Why?
|
| Area Under Curve | 4 | 2021 | 1637 | 0.300 |
Why?
|
| Probability Learning | 1 | 2008 | 23 | 0.300 |
Why?
|
| Sex Factors | 9 | 2022 | 10611 | 0.290 |
Why?
|
| Facial Expression | 2 | 2009 | 514 | 0.290 |
Why?
|
| Decision Making | 3 | 2018 | 3955 | 0.290 |
Why?
|
| Inpatients | 1 | 2019 | 2563 | 0.290 |
Why?
|
| Triazines | 1 | 2009 | 307 | 0.290 |
Why?
|
| Mental Health Services | 2 | 2024 | 1729 | 0.290 |
Why?
|
| Risperidone | 2 | 2007 | 383 | 0.290 |
Why?
|
| Prescriptions | 2 | 2021 | 388 | 0.290 |
Why?
|
| Critical Illness | 1 | 2020 | 2749 | 0.290 |
Why?
|
| Recurrence | 10 | 2014 | 8492 | 0.280 |
Why?
|
| Sexual Dysfunction, Physiological | 2 | 2009 | 363 | 0.280 |
Why?
|
| International Classification of Diseases | 3 | 2020 | 934 | 0.280 |
Why?
|
| Stress, Psychological | 5 | 2014 | 4527 | 0.280 |
Why?
|
| Odds Ratio | 7 | 2022 | 9656 | 0.280 |
Why?
|
| Labor Stage, Second | 2 | 2024 | 45 | 0.270 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2022 | 4055 | 0.270 |
Why?
|
| Social Behavior | 2 | 2016 | 1143 | 0.270 |
Why?
|
| Myocardial Ischemia | 1 | 2017 | 2132 | 0.270 |
Why?
|
| Electroconvulsive Therapy | 3 | 2024 | 505 | 0.270 |
Why?
|
| Health Care Costs | 5 | 2019 | 3241 | 0.270 |
Why?
|
| Behavior Therapy | 1 | 2012 | 886 | 0.270 |
Why?
|
| Dose-Response Relationship, Drug | 12 | 2024 | 10727 | 0.260 |
Why?
|
| Bupropion | 4 | 2014 | 303 | 0.260 |
Why?
|
| Databases, Factual | 5 | 2019 | 8060 | 0.260 |
Why?
|
| Biotransformation | 1 | 2006 | 165 | 0.260 |
Why?
|
| Placenta | 3 | 2024 | 1726 | 0.260 |
Why?
|
| Child | 20 | 2024 | 80568 | 0.260 |
Why?
|
| Apgar Score | 2 | 2024 | 125 | 0.250 |
Why?
|
| Linkage Disequilibrium | 8 | 2012 | 1996 | 0.250 |
Why?
|
| Critical Care | 1 | 2018 | 2713 | 0.250 |
Why?
|
| Cause of Death | 1 | 2016 | 3715 | 0.250 |
Why?
|
| Emotions | 2 | 2015 | 2759 | 0.250 |
Why?
|
| Polymorphism, Genetic | 3 | 2009 | 4249 | 0.250 |
Why?
|
| Physicians | 3 | 2024 | 4591 | 0.250 |
Why?
|
| Telecommunications | 2 | 2020 | 79 | 0.250 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2013 | 2255 | 0.240 |
Why?
|
| Models, Neurological | 1 | 2013 | 1748 | 0.240 |
Why?
|
| Child Abuse | 1 | 2014 | 1090 | 0.240 |
Why?
|
| Dementia | 1 | 2020 | 2741 | 0.240 |
Why?
|
| Cross-Sectional Studies | 10 | 2024 | 26282 | 0.240 |
Why?
|
| Population Groups | 1 | 2006 | 209 | 0.240 |
Why?
|
| Nortriptyline | 3 | 2014 | 79 | 0.230 |
Why?
|
| Emergency Service, Hospital | 2 | 2024 | 7871 | 0.230 |
Why?
|
| Diagnosis, Differential | 5 | 2016 | 12973 | 0.230 |
Why?
|
| Language | 2 | 2024 | 1550 | 0.230 |
Why?
|
| Cost-Benefit Analysis | 4 | 2012 | 5531 | 0.230 |
Why?
|
| Brain Chemistry | 1 | 2008 | 952 | 0.230 |
Why?
|
| Dermatology | 3 | 2018 | 905 | 0.230 |
Why?
|
| Diagnostic Errors | 2 | 2016 | 1276 | 0.230 |
Why?
|
| Infant, Newborn | 11 | 2024 | 26380 | 0.230 |
Why?
|
| Epigenesis, Genetic | 2 | 2014 | 3816 | 0.220 |
Why?
|
| Delivery, Obstetric | 5 | 2024 | 947 | 0.220 |
Why?
|
| Mortality | 1 | 2015 | 2910 | 0.220 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2011 | 1102 | 0.220 |
Why?
|
| Ivermectin | 1 | 2023 | 48 | 0.220 |
Why?
|
| Algorithms | 10 | 2021 | 14064 | 0.210 |
Why?
|
| Prospective Studies | 21 | 2023 | 54807 | 0.210 |
Why?
|
| Electrocardiography | 2 | 2015 | 6409 | 0.210 |
Why?
|
| Child, Preschool | 10 | 2023 | 42510 | 0.210 |
Why?
|
| Research Design | 5 | 2019 | 6204 | 0.210 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 2270 | 0.200 |
Why?
|
| Age of Onset | 7 | 2010 | 3343 | 0.200 |
Why?
|
| Genetic Diseases, Inborn | 2 | 2021 | 606 | 0.200 |
Why?
|
| Patient Satisfaction | 3 | 2013 | 3477 | 0.200 |
Why?
|
| Serotonin | 1 | 2007 | 1046 | 0.200 |
Why?
|
| Membrane Glycoproteins | 4 | 2012 | 3690 | 0.190 |
Why?
|
| Health Surveys | 1 | 2012 | 4058 | 0.190 |
Why?
|
| Wounds and Injuries | 1 | 2014 | 2513 | 0.190 |
Why?
|
| Labor, Obstetric | 2 | 2021 | 313 | 0.190 |
Why?
|
| Reversal Learning | 1 | 2022 | 55 | 0.190 |
Why?
|
| Age Factors | 6 | 2021 | 18382 | 0.190 |
Why?
|
| Cytokines | 4 | 2025 | 7417 | 0.180 |
Why?
|
| Fetal Blood | 3 | 2025 | 1365 | 0.180 |
Why?
|
| Genome | 1 | 2009 | 1753 | 0.180 |
Why?
|
| Risk | 4 | 2019 | 9599 | 0.180 |
Why?
|
| DiGeorge Syndrome | 1 | 2022 | 187 | 0.180 |
Why?
|
| Hydro-Lyases | 1 | 2020 | 93 | 0.180 |
Why?
|
| Blood Urea Nitrogen | 1 | 2020 | 189 | 0.180 |
Why?
|
| Loneliness | 1 | 2023 | 210 | 0.180 |
Why?
|
| Time Factors | 11 | 2020 | 40097 | 0.170 |
Why?
|
| Neuropsychological Tests | 5 | 2021 | 7116 | 0.170 |
Why?
|
| Erythrocyte Count | 1 | 2020 | 157 | 0.170 |
Why?
|
| Clozapine | 2 | 2019 | 509 | 0.170 |
Why?
|
| Physician-Patient Relations | 2 | 2013 | 3270 | 0.170 |
Why?
|
| Medicine | 2 | 2021 | 944 | 0.170 |
Why?
|
| Cholinergic Antagonists | 1 | 2021 | 165 | 0.170 |
Why?
|
| Secondary Prevention | 6 | 2010 | 1470 | 0.170 |
Why?
|
| Labor, Induced | 1 | 2021 | 153 | 0.170 |
Why?
|
| Resilience, Psychological | 2 | 2021 | 808 | 0.170 |
Why?
|
| Sensitivity and Specificity | 7 | 2021 | 14643 | 0.170 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2018 | 627 | 0.170 |
Why?
|
| Chromosome Disorders | 1 | 2022 | 498 | 0.160 |
Why?
|
| Peer Review, Research | 1 | 2023 | 342 | 0.160 |
Why?
|
| Tryptophan Hydroxylase | 2 | 2012 | 93 | 0.160 |
Why?
|
| Hydroxychloroquine | 1 | 2023 | 429 | 0.160 |
Why?
|
| Methylphenidate | 2 | 2024 | 480 | 0.160 |
Why?
|
| Ownership | 1 | 2022 | 338 | 0.160 |
Why?
|
| Astrocytes | 3 | 2022 | 1346 | 0.160 |
Why?
|
| Kynurenic Acid | 1 | 2019 | 44 | 0.160 |
Why?
|
| Analgesics, Opioid | 1 | 2015 | 3834 | 0.160 |
Why?
|
| Cerebrum | 1 | 2020 | 132 | 0.160 |
Why?
|
| Motivation | 2 | 2010 | 2018 | 0.160 |
Why?
|
| Membrane Transport Proteins | 2 | 2005 | 1028 | 0.160 |
Why?
|
| Anticonvulsants | 3 | 2020 | 1919 | 0.160 |
Why?
|
| Drug Administration Schedule | 7 | 2007 | 4851 | 0.160 |
Why?
|
| Calcium Signaling | 1 | 2023 | 733 | 0.150 |
Why?
|
| Electrophysiological Phenomena | 1 | 2020 | 308 | 0.150 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 791 | 0.150 |
Why?
|
| Follow-Up Studies | 8 | 2017 | 39228 | 0.150 |
Why?
|
| Nuclear Proteins | 2 | 2017 | 5782 | 0.150 |
Why?
|
| Ambulatory Care | 6 | 2011 | 2778 | 0.150 |
Why?
|
| Akathisia, Drug-Induced | 2 | 2009 | 66 | 0.150 |
Why?
|
| Incidence | 8 | 2021 | 21513 | 0.150 |
Why?
|
| Amphetamine | 1 | 2019 | 222 | 0.150 |
Why?
|
| Gene Expression Regulation | 5 | 2022 | 11895 | 0.150 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 4 | 2009 | 326 | 0.150 |
Why?
|
| Platelet Count | 1 | 2020 | 784 | 0.140 |
Why?
|
| Minocycline | 1 | 2019 | 168 | 0.140 |
Why?
|
| Histone Deacetylases | 2 | 2020 | 714 | 0.140 |
Why?
|
| Health Status | 3 | 2008 | 4085 | 0.140 |
Why?
|
| Mandatory Reporting | 1 | 2018 | 123 | 0.140 |
Why?
|
| Prognosis | 8 | 2021 | 29890 | 0.140 |
Why?
|
| Health Personnel | 3 | 2021 | 3385 | 0.140 |
Why?
|
| Headache | 2 | 2021 | 1261 | 0.140 |
Why?
|
| Cerebral Cortex | 3 | 2022 | 5765 | 0.140 |
Why?
|
| Ankyrins | 3 | 2017 | 123 | 0.140 |
Why?
|
| Reproducibility of Results | 9 | 2021 | 20133 | 0.140 |
Why?
|
| Mifepristone | 1 | 2018 | 150 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2017 | 6503 | 0.140 |
Why?
|
| Consumer Health Information | 1 | 2019 | 215 | 0.140 |
Why?
|
| Survival Analysis | 5 | 2019 | 10086 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 2 | 2020 | 6058 | 0.140 |
Why?
|
| Insurance Claim Reporting | 1 | 2017 | 166 | 0.130 |
Why?
|
| Ethical Theory | 1 | 2016 | 34 | 0.130 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2018 | 362 | 0.130 |
Why?
|
| Cost of Illness | 4 | 2019 | 1949 | 0.130 |
Why?
|
| Calcium | 3 | 2023 | 5769 | 0.130 |
Why?
|
| Complement C4 | 1 | 2016 | 208 | 0.130 |
Why?
|
| Nerve Net | 1 | 2008 | 2310 | 0.130 |
Why?
|
| Receptors, Oxytocin | 1 | 2016 | 71 | 0.130 |
Why?
|
| Cells, Cultured | 4 | 2019 | 18962 | 0.130 |
Why?
|
| Docosahexaenoic Acids | 2 | 2020 | 916 | 0.130 |
Why?
|
| Phosphocreatine | 1 | 2016 | 259 | 0.130 |
Why?
|
| Markov Chains | 2 | 2012 | 971 | 0.130 |
Why?
|
| Hydrocarbons, Iodinated | 1 | 2015 | 8 | 0.130 |
Why?
|
| Rare Diseases | 1 | 2021 | 629 | 0.130 |
Why?
|
| Physicians, Women | 1 | 2022 | 516 | 0.120 |
Why?
|
| Eosinophils | 1 | 2020 | 946 | 0.120 |
Why?
|
| Quality of Health Care | 2 | 2013 | 4305 | 0.120 |
Why?
|
| Haplotypes | 5 | 2008 | 2726 | 0.120 |
Why?
|
| Current Procedural Terminology | 1 | 2016 | 100 | 0.120 |
Why?
|
| Europe | 3 | 2017 | 3430 | 0.120 |
Why?
|
| Troponin T | 1 | 2020 | 785 | 0.120 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 746 | 0.120 |
Why?
|
| Oxazoles | 1 | 2016 | 198 | 0.120 |
Why?
|
| Fatigue | 1 | 2022 | 1553 | 0.120 |
Why?
|
| Electronic Prescribing | 1 | 2016 | 115 | 0.120 |
Why?
|
| Neurodegenerative Diseases | 2 | 2016 | 1086 | 0.120 |
Why?
|
| Buspirone | 2 | 2012 | 80 | 0.120 |
Why?
|
| Cyclohexanols | 2 | 2012 | 126 | 0.120 |
Why?
|
| Creatinine | 1 | 2020 | 1916 | 0.120 |
Why?
|
| Publication Bias | 2 | 2005 | 157 | 0.120 |
Why?
|
| Membrane Potentials | 2 | 2015 | 1084 | 0.120 |
Why?
|
| Sodium-Bicarbonate Symporters | 1 | 2014 | 30 | 0.120 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2024 | 1176 | 0.120 |
Why?
|
| Drug Combinations | 2 | 2012 | 2075 | 0.120 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 2227 | 0.120 |
Why?
|
| Positron-Emission Tomography | 4 | 2020 | 6542 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 2 | 2012 | 1729 | 0.110 |
Why?
|
| Models, Theoretical | 3 | 2017 | 3560 | 0.110 |
Why?
|
| Judgment | 1 | 2016 | 270 | 0.110 |
Why?
|
| Neuroma, Acoustic | 1 | 2018 | 456 | 0.110 |
Why?
|
| Amitriptyline | 1 | 2014 | 110 | 0.110 |
Why?
|
| Violence | 1 | 2020 | 931 | 0.110 |
Why?
|
| Cadherins | 1 | 2019 | 899 | 0.110 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2018 | 1167 | 0.110 |
Why?
|
| Interneurons | 1 | 2019 | 593 | 0.110 |
Why?
|
| Anorexia Nervosa | 1 | 2023 | 1328 | 0.110 |
Why?
|
| Fructose | 1 | 2016 | 285 | 0.110 |
Why?
|
| Texas | 2 | 2005 | 410 | 0.110 |
Why?
|
| Sertraline | 2 | 2012 | 209 | 0.110 |
Why?
|
| Insurance | 1 | 2015 | 115 | 0.110 |
Why?
|
| Outpatients | 3 | 2019 | 1595 | 0.110 |
Why?
|
| Combined Modality Therapy | 5 | 2012 | 8522 | 0.110 |
Why?
|
| Isotope Labeling | 1 | 2015 | 389 | 0.110 |
Why?
|
| Perinatal Care | 1 | 2016 | 243 | 0.110 |
Why?
|
| Artificial Intelligence | 2 | 2022 | 2661 | 0.110 |
Why?
|
| Morals | 1 | 2016 | 288 | 0.110 |
Why?
|
| Alcohol-Related Disorders | 1 | 2016 | 242 | 0.110 |
Why?
|
| Dopamine Agonists | 2 | 2013 | 346 | 0.110 |
Why?
|
| Oxygen | 2 | 2019 | 4246 | 0.110 |
Why?
|
| Placebos | 3 | 2006 | 1659 | 0.110 |
Why?
|
| Heart Failure | 1 | 2017 | 11837 | 0.110 |
Why?
|
| Penetrance | 1 | 2015 | 388 | 0.100 |
Why?
|
| Regression Analysis | 4 | 2016 | 6321 | 0.100 |
Why?
|
| Medical Records | 1 | 2018 | 1408 | 0.100 |
Why?
|
| England | 1 | 2014 | 533 | 0.100 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2023 | 2897 | 0.100 |
Why?
|
| Infant | 5 | 2024 | 36426 | 0.100 |
Why?
|
| Tablets | 1 | 2013 | 149 | 0.100 |
Why?
|
| Phosphates | 1 | 2016 | 763 | 0.100 |
Why?
|
| Meta-Analysis as Topic | 2 | 2016 | 1366 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2012 | 8924 | 0.100 |
Why?
|
| Repressor Proteins | 1 | 2023 | 2969 | 0.100 |
Why?
|
| Propensity Score | 2 | 2018 | 1971 | 0.100 |
Why?
|
| Health Behavior | 1 | 2024 | 2649 | 0.100 |
Why?
|
| Child Development Disorders, Pervasive | 2 | 2014 | 597 | 0.100 |
Why?
|
| Drug Substitution | 2 | 2012 | 292 | 0.100 |
Why?
|
| Demography | 4 | 2006 | 1640 | 0.100 |
Why?
|
| Cell Line | 3 | 2022 | 15540 | 0.100 |
Why?
|
| Receptor, Melanocortin, Type 3 | 1 | 2012 | 12 | 0.100 |
Why?
|
| Delayed Diagnosis | 1 | 2016 | 452 | 0.100 |
Why?
|
| Dopamine beta-Hydroxylase | 2 | 2009 | 74 | 0.100 |
Why?
|
| Wireless Technology | 1 | 2013 | 99 | 0.100 |
Why?
|
| Executive Function | 2 | 2024 | 1391 | 0.100 |
Why?
|
| Macrophages | 2 | 2024 | 5772 | 0.100 |
Why?
|
| Information Dissemination | 1 | 2020 | 1142 | 0.100 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 2 | 2009 | 61 | 0.100 |
Why?
|
| Functional Laterality | 2 | 2017 | 2243 | 0.100 |
Why?
|
| Sex Characteristics | 2 | 2021 | 2645 | 0.100 |
Why?
|
| Pilot Projects | 5 | 2013 | 8724 | 0.100 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 12059 | 0.100 |
Why?
|
| Ketamine | 1 | 2018 | 527 | 0.100 |
Why?
|
| Disease | 1 | 2017 | 674 | 0.100 |
Why?
|
| Telemetry | 1 | 2013 | 201 | 0.100 |
Why?
|
| Genome, Human | 4 | 2021 | 4443 | 0.100 |
Why?
|
| Crohn Disease | 3 | 2013 | 2281 | 0.100 |
Why?
|
| Psychomotor Performance | 3 | 2011 | 1882 | 0.100 |
Why?
|
| Acute Disease | 1 | 2022 | 7236 | 0.100 |
Why?
|
| Reinforcement Schedule | 2 | 2010 | 123 | 0.100 |
Why?
|
| Drug Synergism | 2 | 2013 | 1751 | 0.090 |
Why?
|
| Registries | 3 | 2019 | 8346 | 0.090 |
Why?
|
| RNA, Untranslated | 1 | 2015 | 454 | 0.090 |
Why?
|
| Patient Selection | 3 | 2020 | 4248 | 0.090 |
Why?
|
| Mothers | 1 | 2022 | 2206 | 0.090 |
Why?
|
| Learning | 2 | 2011 | 1754 | 0.090 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2016 | 3678 | 0.090 |
Why?
|
| Quality of Life | 6 | 2009 | 13463 | 0.090 |
Why?
|
| Gene Frequency | 5 | 2010 | 3623 | 0.090 |
Why?
|
| Socioeconomic Factors | 2 | 2009 | 7842 | 0.090 |
Why?
|
| Monocytes | 1 | 2020 | 2591 | 0.090 |
Why?
|
| Disease Susceptibility | 2 | 2023 | 1787 | 0.090 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 4641 | 0.090 |
Why?
|
| Triazoles | 1 | 2016 | 898 | 0.090 |
Why?
|
| Models, Psychological | 1 | 2015 | 823 | 0.090 |
Why?
|
| Colitis, Ulcerative | 2 | 2013 | 1912 | 0.090 |
Why?
|
| Cell Differentiation | 4 | 2023 | 11639 | 0.090 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2020 | 1399 | 0.090 |
Why?
|
| Models, Genetic | 1 | 2020 | 3447 | 0.090 |
Why?
|
| Mother-Child Relations | 1 | 2014 | 498 | 0.090 |
Why?
|
| Synaptosomal-Associated Protein 25 | 2 | 2007 | 50 | 0.090 |
Why?
|
| Oxidative Stress | 2 | 2019 | 3140 | 0.090 |
Why?
|
| Receptor, Melanocortin, Type 2 | 1 | 2009 | 9 | 0.090 |
Why?
|
| Substance-Related Disorders | 5 | 2018 | 4418 | 0.090 |
Why?
|
| Receptors, Histamine H1 | 1 | 2009 | 20 | 0.090 |
Why?
|
| Receptors, CXCR4 | 1 | 2015 | 729 | 0.090 |
Why?
|
| GABA Modulators | 1 | 2010 | 108 | 0.090 |
Why?
|
| Genetic Testing | 2 | 2021 | 3594 | 0.080 |
Why?
|
| Guideline Adherence | 3 | 2010 | 2234 | 0.080 |
Why?
|
| Oxidation-Reduction | 1 | 2016 | 2219 | 0.080 |
Why?
|
| Neuroleptic Malignant Syndrome | 1 | 2010 | 74 | 0.080 |
Why?
|
| Postpartum Period | 1 | 2017 | 1195 | 0.080 |
Why?
|
| Psychomotor Agitation | 2 | 2020 | 307 | 0.080 |
Why?
|
| Animals | 13 | 2024 | 168735 | 0.080 |
Why?
|
| Limbic System | 1 | 2012 | 418 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2020 | 36547 | 0.080 |
Why?
|
| Primary Health Care | 2 | 2019 | 4736 | 0.080 |
Why?
|
| Receptors, Dopamine D2 | 2 | 2009 | 471 | 0.080 |
Why?
|
| Bronchiolitis | 1 | 2016 | 492 | 0.080 |
Why?
|
| Causality | 1 | 2016 | 1247 | 0.080 |
Why?
|
| Ventral Tegmental Area | 1 | 2010 | 136 | 0.080 |
Why?
|
| Insurance, Health | 2 | 2019 | 2520 | 0.080 |
Why?
|
| Information Storage and Retrieval | 1 | 2015 | 831 | 0.080 |
Why?
|
| Lorazepam | 1 | 2010 | 155 | 0.080 |
Why?
|
| Receptors, Dopamine D3 | 1 | 2009 | 106 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2010 | 412 | 0.080 |
Why?
|
| Attention | 4 | 2024 | 2413 | 0.080 |
Why?
|
| Cyclothymic Disorder | 1 | 2009 | 42 | 0.080 |
Why?
|
| Receptors, Mineralocorticoid | 1 | 2010 | 167 | 0.080 |
Why?
|
| Receptor, Serotonin, 5-HT1B | 2 | 2005 | 36 | 0.080 |
Why?
|
| Basal Ganglia Diseases | 1 | 2009 | 145 | 0.080 |
Why?
|
| Alcoholism | 2 | 2010 | 1978 | 0.080 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2011 | 457 | 0.080 |
Why?
|
| Substantia Nigra | 1 | 2010 | 346 | 0.080 |
Why?
|
| Treatment Failure | 3 | 2022 | 2653 | 0.080 |
Why?
|
| Parity | 2 | 2023 | 931 | 0.080 |
Why?
|
| North America | 1 | 2012 | 1287 | 0.080 |
Why?
|
| Calibration | 1 | 2011 | 812 | 0.080 |
Why?
|
| Glucose | 1 | 2020 | 4335 | 0.080 |
Why?
|
| Empathy | 1 | 2013 | 474 | 0.080 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 3851 | 0.080 |
Why?
|
| Internet | 2 | 2019 | 3106 | 0.080 |
Why?
|
| Statistics as Topic | 1 | 2015 | 2350 | 0.080 |
Why?
|
| Dermatitis, Atopic | 1 | 2016 | 724 | 0.080 |
Why?
|
| Energy Metabolism | 1 | 2019 | 2894 | 0.080 |
Why?
|
| Endpoint Determination | 1 | 2011 | 591 | 0.080 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2013 | 632 | 0.080 |
Why?
|
| Boston | 2 | 2018 | 9334 | 0.080 |
Why?
|
| Cytoskeletal Proteins | 2 | 2017 | 1322 | 0.080 |
Why?
|
| Benzophenones | 1 | 2008 | 58 | 0.070 |
Why?
|
| Body Mass Index | 5 | 2024 | 13042 | 0.070 |
Why?
|
| Reference Standards | 1 | 2012 | 1011 | 0.070 |
Why?
|
| Myosin Type V | 1 | 2008 | 31 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2009 | 378 | 0.070 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2010 | 780 | 0.070 |
Why?
|
| Nitrophenols | 1 | 2008 | 169 | 0.070 |
Why?
|
| Neutrophils | 1 | 2020 | 3769 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2016 | 12529 | 0.070 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2009 | 308 | 0.070 |
Why?
|
| Sialyltransferases | 1 | 2008 | 83 | 0.070 |
Why?
|
| Episode of Care | 2 | 2005 | 127 | 0.070 |
Why?
|
| Hostility | 1 | 2008 | 185 | 0.070 |
Why?
|
| Dibenzothiazepines | 1 | 2007 | 101 | 0.070 |
Why?
|
| Premature Birth | 2 | 2017 | 1830 | 0.070 |
Why?
|
| Drug Monitoring | 1 | 2013 | 960 | 0.070 |
Why?
|
| Muscle Proteins | 1 | 2012 | 1160 | 0.070 |
Why?
|
| Personality | 1 | 2010 | 559 | 0.070 |
Why?
|
| Dominance, Cerebral | 1 | 2008 | 616 | 0.070 |
Why?
|
| Glutamic Acid | 1 | 2012 | 1181 | 0.070 |
Why?
|
| Gene Expression | 3 | 2015 | 7581 | 0.070 |
Why?
|
| Hyperprolactinemia | 1 | 2007 | 122 | 0.070 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2007 | 108 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 1 | 2015 | 2233 | 0.070 |
Why?
|
| Evidence-Based Medicine | 3 | 2011 | 3690 | 0.070 |
Why?
|
| Rodentia | 1 | 2008 | 263 | 0.070 |
Why?
|
| Synaptic Transmission | 1 | 2012 | 1178 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2018 | 3953 | 0.070 |
Why?
|
| Myosin Heavy Chains | 1 | 2008 | 403 | 0.070 |
Why?
|
| Drug Evaluation | 1 | 2007 | 642 | 0.070 |
Why?
|
| Association Learning | 1 | 2008 | 219 | 0.070 |
Why?
|
| Discrimination Learning | 1 | 2008 | 276 | 0.060 |
Why?
|
| Fetus | 2 | 2024 | 1878 | 0.060 |
Why?
|
| Least-Squares Analysis | 1 | 2006 | 368 | 0.060 |
Why?
|
| Medicaid | 1 | 2019 | 2833 | 0.060 |
Why?
|
| Drugs, Generic | 1 | 2011 | 457 | 0.060 |
Why?
|
| tau Proteins | 1 | 2016 | 2110 | 0.060 |
Why?
|
| Mutation, Missense | 2 | 2016 | 2589 | 0.060 |
Why?
|
| Monitoring, Physiologic | 1 | 2013 | 1793 | 0.060 |
Why?
|
| Mental Health | 1 | 2020 | 3272 | 0.060 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2010 | 698 | 0.060 |
Why?
|
| Neurogenesis | 2 | 2023 | 863 | 0.060 |
Why?
|
| Linear Models | 1 | 2015 | 5873 | 0.060 |
Why?
|
| Radiopharmaceuticals | 1 | 2015 | 2701 | 0.060 |
Why?
|
| Frontal Lobe | 2 | 2009 | 1408 | 0.060 |
Why?
|
| Predictive Value of Tests | 5 | 2014 | 15401 | 0.060 |
Why?
|
| Twin Studies as Topic | 1 | 2005 | 103 | 0.060 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2010 | 1138 | 0.060 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2005 | 219 | 0.060 |
Why?
|
| Appetite | 1 | 2006 | 247 | 0.060 |
Why?
|
| Cardiotocography | 1 | 2024 | 33 | 0.060 |
Why?
|
| Metabolic Diseases | 2 | 2024 | 686 | 0.060 |
Why?
|
| Leptin | 1 | 2012 | 1596 | 0.060 |
Why?
|
| Educational Status | 1 | 2012 | 2510 | 0.060 |
Why?
|
| Gestational Age | 2 | 2024 | 3616 | 0.060 |
Why?
|
| Neurotransmitter Agents | 1 | 2008 | 663 | 0.060 |
Why?
|
| Psychometrics | 5 | 2016 | 3061 | 0.060 |
Why?
|
| MicroRNAs | 2 | 2023 | 3788 | 0.060 |
Why?
|
| Quinolones | 1 | 2007 | 387 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 3796 | 0.060 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2015 | 1481 | 0.060 |
Why?
|
| Self Concept | 1 | 2010 | 1039 | 0.060 |
Why?
|
| Infant, Small for Gestational Age | 2 | 2017 | 468 | 0.060 |
Why?
|
| Amphetamines | 1 | 2024 | 142 | 0.060 |
Why?
|
| Hepatic Artery | 1 | 2005 | 233 | 0.050 |
Why?
|
| Glycogen Synthase Kinase 3 | 2 | 2016 | 414 | 0.050 |
Why?
|
| Triiodothyronine | 1 | 2005 | 493 | 0.050 |
Why?
|
| Focal Adhesions | 1 | 2024 | 113 | 0.050 |
Why?
|
| Dizziness | 1 | 2006 | 268 | 0.050 |
Why?
|
| RNA, Messenger | 3 | 2015 | 12768 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 2844 | 0.050 |
Why?
|
| Mohs Surgery | 1 | 2006 | 217 | 0.050 |
Why?
|
| Pedigree | 2 | 2008 | 4535 | 0.050 |
Why?
|
| Neuropeptides | 1 | 2008 | 952 | 0.050 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 3407 | 0.050 |
Why?
|
| Health Care Surveys | 2 | 2007 | 2426 | 0.050 |
Why?
|
| Patient Care Management | 1 | 2006 | 301 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 10 | 2 | 2017 | 275 | 0.050 |
Why?
|
| Sleep Stages | 1 | 2006 | 705 | 0.050 |
Why?
|
| RNA | 2 | 2022 | 2716 | 0.050 |
Why?
|
| Evoked Potentials | 2 | 2011 | 1048 | 0.050 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2009 | 1740 | 0.050 |
Why?
|
| Evidence-Based Practice | 1 | 2007 | 499 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2011 | 4520 | 0.050 |
Why?
|
| Obstetric Labor Complications | 1 | 2024 | 239 | 0.050 |
Why?
|
| Choice Behavior | 1 | 2008 | 846 | 0.050 |
Why?
|
| Time | 1 | 2004 | 549 | 0.050 |
Why?
|
| Androgens | 1 | 2009 | 1278 | 0.050 |
Why?
|
| Activities of Daily Living | 1 | 2011 | 2414 | 0.050 |
Why?
|
| Orgasm | 1 | 2002 | 63 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 7473 | 0.050 |
Why?
|
| Neurosecretory Systems | 1 | 2003 | 223 | 0.050 |
Why?
|
| Memory, Short-Term | 1 | 2008 | 1002 | 0.050 |
Why?
|
| Antiparkinson Agents | 1 | 2002 | 184 | 0.050 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 5509 | 0.050 |
Why?
|
| Mental Recall | 1 | 2008 | 1217 | 0.050 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 2 | 2016 | 300 | 0.050 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2012 | 2415 | 0.050 |
Why?
|
| Sulfurtransferases | 1 | 2021 | 17 | 0.050 |
Why?
|
| Libido | 1 | 2002 | 123 | 0.050 |
Why?
|
| Computer Simulation | 2 | 2012 | 6251 | 0.050 |
Why?
|
| Calcium Channels | 2 | 2015 | 622 | 0.050 |
Why?
|
| Ghrelin | 1 | 2023 | 255 | 0.050 |
Why?
|
| Medicare | 1 | 2019 | 6815 | 0.050 |
Why?
|
| Mass Screening | 1 | 2017 | 5449 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2022 | 340 | 0.050 |
Why?
|
| Interview, Psychological | 1 | 2004 | 811 | 0.040 |
Why?
|
| Malpractice | 1 | 2006 | 561 | 0.040 |
Why?
|
| Drug Design | 1 | 2006 | 1039 | 0.040 |
Why?
|
| Calcinosis | 1 | 2009 | 1475 | 0.040 |
Why?
|
| Presynaptic Terminals | 1 | 2022 | 298 | 0.040 |
Why?
|
| Dyslipidemias | 1 | 2007 | 871 | 0.040 |
Why?
|
| Thiazoles | 1 | 2007 | 1528 | 0.040 |
Why?
|
| Obsessive-Compulsive Disorder | 2 | 2007 | 1485 | 0.040 |
Why?
|
| Electroencephalography | 2 | 2008 | 6274 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2010 | 2688 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2008 | 1995 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 5691 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2005 | 1009 | 0.040 |
Why?
|
| Chromosome Mapping | 4 | 2010 | 4617 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2008 | 4111 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2008 | 1673 | 0.040 |
Why?
|
| Mice | 6 | 2024 | 81782 | 0.040 |
Why?
|
| Homozygote | 2 | 2016 | 1774 | 0.040 |
Why?
|
| Chromosomes, Human | 1 | 2021 | 437 | 0.040 |
Why?
|
| Paroxetine | 1 | 2020 | 181 | 0.040 |
Why?
|
| Microelectrodes | 1 | 2020 | 305 | 0.040 |
Why?
|
| Program Evaluation | 2 | 2006 | 2502 | 0.040 |
Why?
|
| Testosterone | 1 | 2009 | 2495 | 0.040 |
Why?
|
| Diabetes Mellitus | 2 | 2015 | 5889 | 0.040 |
Why?
|
| Stochastic Processes | 1 | 2020 | 358 | 0.040 |
Why?
|
| Family | 2 | 2007 | 3208 | 0.040 |
Why?
|
| Cooperative Behavior | 1 | 2006 | 1512 | 0.040 |
Why?
|
| Life Expectancy | 1 | 2005 | 1247 | 0.040 |
Why?
|
| Erectile Dysfunction | 1 | 2002 | 437 | 0.040 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2024 | 587 | 0.040 |
Why?
|
| Major Histocompatibility Complex | 1 | 2021 | 879 | 0.040 |
Why?
|
| Cardiovascular Diseases | 4 | 2009 | 15645 | 0.040 |
Why?
|
| Microarray Analysis | 1 | 2021 | 752 | 0.040 |
Why?
|
| Anisotropy | 2 | 2012 | 1284 | 0.040 |
Why?
|
| Likelihood Functions | 2 | 2011 | 993 | 0.040 |
Why?
|
| Chromosome Deletion | 1 | 2022 | 1384 | 0.040 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2021 | 658 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 3716 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2015 | 1657 | 0.040 |
Why?
|
| Membrane Proteins | 2 | 2012 | 7847 | 0.040 |
Why?
|
| Gene Duplication | 1 | 2018 | 316 | 0.040 |
Why?
|
| Neuroprotective Agents | 2 | 2016 | 959 | 0.040 |
Why?
|
| Parturition | 1 | 2021 | 453 | 0.040 |
Why?
|
| Nerve Growth Factors | 1 | 2020 | 564 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2022 | 1601 | 0.030 |
Why?
|
| Hypertension | 2 | 2015 | 8616 | 0.030 |
Why?
|
| Acid Anhydride Hydrolases | 1 | 2016 | 67 | 0.030 |
Why?
|
| Piperazines | 1 | 2007 | 2546 | 0.030 |
Why?
|
| Telemedicine | 2 | 2024 | 3108 | 0.030 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor Receptors | 1 | 2016 | 13 | 0.030 |
Why?
|
| Genetic Markers | 3 | 2008 | 2603 | 0.030 |
Why?
|
| Aminopeptidases | 1 | 2017 | 113 | 0.030 |
Why?
|
| Pregnancy Trimesters | 1 | 2017 | 197 | 0.030 |
Why?
|
| Dimethylformamide | 1 | 2015 | 20 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2019 | 23597 | 0.030 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2017 | 237 | 0.030 |
Why?
|
| Smoking | 2 | 2009 | 9082 | 0.030 |
Why?
|
| Systems Biology | 1 | 2019 | 481 | 0.030 |
Why?
|
| Pain | 1 | 2010 | 5077 | 0.030 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 2 | 2010 | 410 | 0.030 |
Why?
|
| Phosphorus | 1 | 2016 | 336 | 0.030 |
Why?
|
| International Cooperation | 2 | 2013 | 1433 | 0.030 |
Why?
|
| Calcium Channel Agonists | 1 | 2014 | 26 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2024 | 2455 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2019 | 1527 | 0.030 |
Why?
|
| Genomics | 2 | 2022 | 5925 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2005 | 2170 | 0.030 |
Why?
|
| Numerical Analysis, Computer-Assisted | 1 | 2015 | 120 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2013 | 18292 | 0.030 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2022 | 1353 | 0.030 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2015 | 204 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2024 | 2877 | 0.030 |
Why?
|
| Indoles | 1 | 2002 | 1833 | 0.030 |
Why?
|
| Genetic Linkage | 2 | 2010 | 2342 | 0.030 |
Why?
|
| Transcription Factors | 4 | 2015 | 12129 | 0.030 |
Why?
|
| Half-Life | 1 | 2015 | 645 | 0.030 |
Why?
|
| Carbon Radioisotopes | 1 | 2015 | 543 | 0.030 |
Why?
|
| Editorial Policies | 1 | 2018 | 458 | 0.030 |
Why?
|
| Hematopoietic Cell Growth Factors | 1 | 1993 | 98 | 0.030 |
Why?
|
| Intelligence Tests | 1 | 2014 | 504 | 0.030 |
Why?
|
| Integrins | 1 | 2017 | 838 | 0.030 |
Why?
|
| Permeability | 1 | 2015 | 726 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2021 | 2136 | 0.030 |
Why?
|
| Self-Injurious Behavior | 1 | 2019 | 572 | 0.030 |
Why?
|
| Sweden | 1 | 2015 | 1381 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2020 | 2036 | 0.020 |
Why?
|
| Genes, Mitochondrial | 1 | 2012 | 59 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2022 | 22327 | 0.020 |
Why?
|
| Lipids | 1 | 2023 | 3317 | 0.020 |
Why?
|
| Child Development | 1 | 2024 | 2327 | 0.020 |
Why?
|
| Fornix, Brain | 1 | 2012 | 71 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2024 | 4405 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2016 | 1880 | 0.020 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2018 | 1195 | 0.020 |
Why?
|
| ADAM Proteins | 1 | 2013 | 243 | 0.020 |
Why?
|
| Reference Values | 2 | 2010 | 4909 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2014 | 898 | 0.020 |
Why?
|
| Obesity | 2 | 2023 | 13082 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2016 | 1944 | 0.020 |
Why?
|
| Behavior | 1 | 2014 | 536 | 0.020 |
Why?
|
| Free Radical Scavengers | 1 | 2012 | 213 | 0.020 |
Why?
|
| Feedback, Psychological | 1 | 2011 | 97 | 0.020 |
Why?
|
| Brain Mapping | 3 | 2011 | 6598 | 0.020 |
Why?
|
| Inheritance Patterns | 1 | 2013 | 345 | 0.020 |
Why?
|
| Feasibility Studies | 2 | 2012 | 5300 | 0.020 |
Why?
|
| China | 1 | 2017 | 2383 | 0.020 |
Why?
|
| Medial Forebrain Bundle | 1 | 2010 | 42 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2014 | 1336 | 0.020 |
Why?
|
| Income | 1 | 2019 | 1874 | 0.020 |
Why?
|
| Adrenomedullin | 1 | 2010 | 85 | 0.020 |
Why?
|
| Bromocriptine | 1 | 2010 | 93 | 0.020 |
Why?
|
| Beauty | 1 | 2010 | 41 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2013 | 15802 | 0.020 |
Why?
|
| Family Health | 1 | 2015 | 1253 | 0.020 |
Why?
|
| Oxidative Phosphorylation | 1 | 2012 | 502 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 3230 | 0.020 |
Why?
|
| Genetic Heterogeneity | 1 | 2013 | 735 | 0.020 |
Why?
|
| Stem Cells | 1 | 2022 | 3537 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 3430 | 0.020 |
Why?
|
| Receptors, Kainic Acid | 1 | 2009 | 91 | 0.020 |
Why?
|
| Delphi Technique | 1 | 2013 | 893 | 0.020 |
Why?
|
| Diazepam | 1 | 2010 | 215 | 0.020 |
Why?
|
| Electrolytes | 1 | 2010 | 279 | 0.020 |
Why?
|
| Advisory Committees | 1 | 2013 | 796 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2009 | 860 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2005 | 4349 | 0.020 |
Why?
|
| Euphoria | 1 | 2009 | 64 | 0.020 |
Why?
|
| Breast Feeding | 1 | 2017 | 1363 | 0.020 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2009 | 151 | 0.020 |
Why?
|
| Cost Savings | 1 | 2014 | 900 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2017 | 2353 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2011 | 999 | 0.020 |
Why?
|
| Personality Assessment | 1 | 2010 | 646 | 0.020 |
Why?
|
| Haloperidol | 1 | 2010 | 394 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2021 | 3586 | 0.020 |
Why?
|
| Glycolysis | 1 | 2012 | 837 | 0.020 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2009 | 287 | 0.020 |
Why?
|
| Phosphorylation | 2 | 2016 | 8279 | 0.020 |
Why?
|
| Rats | 2 | 2015 | 23708 | 0.020 |
Why?
|
| Cognition Disorders | 2 | 2014 | 3965 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 2009 | 712 | 0.020 |
Why?
|
| Catatonia | 1 | 2010 | 181 | 0.020 |
Why?
|
| Neoplasm Proteins | 2 | 2016 | 3592 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2008 | 361 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2008 | 432 | 0.020 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2010 | 369 | 0.020 |
Why?
|
| Basal Ganglia | 1 | 2010 | 549 | 0.020 |
Why?
|
| Health Expenditures | 1 | 2019 | 2388 | 0.020 |
Why?
|
| Fluid Therapy | 1 | 2010 | 587 | 0.020 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2012 | 952 | 0.020 |
Why?
|
| Observer Variation | 1 | 2012 | 2611 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2016 | 5377 | 0.020 |
Why?
|
| Gyrus Cinguli | 1 | 2012 | 1116 | 0.020 |
Why?
|
| Food | 1 | 2010 | 764 | 0.020 |
Why?
|
| Receptors, Dopamine D5 | 1 | 2005 | 32 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2005 | 6958 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2012 | 2925 | 0.010 |
Why?
|
| Adoption | 1 | 2005 | 97 | 0.010 |
Why?
|
| Pulse | 1 | 2004 | 217 | 0.010 |
Why?
|
| Receptors, Dopamine D4 | 1 | 2005 | 168 | 0.010 |
Why?
|
| Liability, Legal | 1 | 2006 | 209 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2014 | 4161 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1993 | 2423 | 0.010 |
Why?
|
| Medical History Taking | 1 | 2008 | 779 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 8107 | 0.010 |
Why?
|
| DNA | 2 | 2008 | 7193 | 0.010 |
Why?
|
| User-Computer Interface | 1 | 2010 | 1404 | 0.010 |
Why?
|
| Tourette Syndrome | 1 | 2007 | 400 | 0.010 |
Why?
|
| Photic Stimulation | 1 | 2010 | 1992 | 0.010 |
Why?
|
| Consensus | 1 | 2013 | 3202 | 0.010 |
Why?
|
| Receptors, Dopamine D1 | 1 | 2005 | 276 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2007 | 12235 | 0.010 |
Why?
|
| Behavior, Addictive | 1 | 2008 | 423 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2019 | 14450 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2012 | 4130 | 0.010 |
Why?
|
| Motor Activity | 1 | 2013 | 2705 | 0.010 |
Why?
|
| Life Change Events | 1 | 2008 | 956 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2016 | 4041 | 0.010 |
Why?
|
| Drug Utilization | 1 | 2009 | 1187 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2010 | 2740 | 0.010 |
Why?
|
| Fathers | 1 | 2005 | 377 | 0.010 |
Why?
|
| Movement | 1 | 2009 | 1460 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 13631 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 8603 | 0.010 |
Why?
|
| Placebo Effect | 1 | 2006 | 515 | 0.010 |
Why?
|
| Heart Rate | 1 | 2013 | 4203 | 0.010 |
Why?
|
| Seizures | 1 | 2014 | 2997 | 0.010 |
Why?
|
| Amygdala | 1 | 2009 | 1376 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 17060 | 0.010 |
Why?
|
| Molecular Biology | 1 | 2005 | 573 | 0.010 |
Why?
|
| Postmenopause | 1 | 2009 | 2517 | 0.010 |
Why?
|
| Women's Health | 1 | 2009 | 2081 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2010 | 3558 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 2006 | 1435 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2003 | 20690 | 0.010 |
Why?
|
| Panic Disorder | 1 | 2003 | 611 | 0.010 |
Why?
|
| Hypercholesterolemia | 1 | 2007 | 1148 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2006 | 2108 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2010 | 4780 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 2007 | 1389 | 0.010 |
Why?
|
| Medical Errors | 1 | 2006 | 1258 | 0.010 |
Why?
|
| Sleep | 1 | 2013 | 4818 | 0.010 |
Why?
|
| Asthma | 1 | 2016 | 6268 | 0.010 |
Why?
|
| Hippocampus | 1 | 2009 | 3772 | 0.010 |
Why?
|
| Data Collection | 1 | 2006 | 3318 | 0.010 |
Why?
|
| Base Sequence | 1 | 2007 | 12405 | 0.010 |
Why?
|
| Cholesterol | 1 | 2004 | 2902 | 0.010 |
Why?
|
| Melanoma | 1 | 1993 | 5695 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2010 | 4856 | 0.010 |
Why?
|
| Stem Cell Factor | 1 | 1993 | 194 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1993 | 745 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2004 | 6422 | 0.010 |
Why?
|
| Mutation | 1 | 2014 | 30192 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 1993 | 723 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2004 | 8530 | 0.000 |
Why?
|
| Cell Division | 1 | 1993 | 4466 | 0.000 |
Why?
|
| Tumor Cells, Cultured | 1 | 1993 | 6101 | 0.000 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2003 | 4627 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1993 | 13398 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1993 | 17596 | 0.000 |
Why?
|